Emflaza is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients at the age of 5 and older.
: Lupin
: Duchenne Muscular Dystrophy / DMD
6mg × 180 Tabletten
€ 119.42
€ 0.66
€ 211.14
6mg × 120 Tabletten
€ 91.85
€ 0.77
€ 128.52
6mg × 90 Tabletten
€ 82.66
€ 0.92
€ 82.62
6mg × 60 Tabletten
€ 68.88
€ 1.15
€ 41.31
6mg × 30 Tabletten
€ 55.09
€ 1.84
Deflazacort tablets
What is this medicine?
Deflazacort a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.
What should I tell my health care providers before I take this medicine?
They need to know if you have any of these conditions:
Hypersensitivity to deflazacort;
Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia;
Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal;
Alterations in Cardiovascular/Renal Function: elevated blood pressure and sodium, and for decreased potassium level;
Gastrointestinal Perforation: GI disorders;
Behavioral and Mood Disturbances: euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis;
Effects on Bones: decreases in bone mineral density;
Serious Skin Rashes;
Ophthalmic Effects: May include cataracts, infections, and glaucoma;
Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids.
How should I use this medicine?
The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally. Discontinue gradually when administered for more than a few day..
What may interact with this medicine?
Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage;
Avoid use of moderate or strong CYP3A4 inducers, as they may reduce efficacy.
What side effects may I notice from this medicine?
The most common adverse reactions are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis.